Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Karolina Piejko
Observed name:
K. Piejko
Institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institutions:
Medical University of Warsaw,
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0000-0002-0256-9220
Observed ORCID:
0000-0002-0256-9220
OpenAlex ID:
A5044178368
Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence
2020
·
Bożena Cybulska-Stopa
, Paweł Rogala
, et al.
·
Advances in Medical Sciences
·
18
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment
2023
·
Bożena Cybulska-Stopa
, Karolina Piejko
, et al.
·
Melanoma Research
·
17
First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland
2020
·
Bożena Cybulska-Stopa
, Renata Pacholczak-Madej
, et al.
·
Immunotherapy
·
17
Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
2020
·
Bożena Cybulska-Stopa
, Iwona Ługowska
, et al.
·
Współczesna Onkologia
·
17
PDF
Real-world treatment practice in patients with advanced melanoma
2020
·
Bożena Cybulska-Stopa
, Karolina Piejko
, et al.
·
Współczesna Onkologia
·
16
PDF
Using thermal imaging to assess the effect of classical massage on selected physiological parameters of upper limbs
2014
·
Dariusz Boguszewski
, Jakub Grzegorz Adamczyk
, et al.
·
Biomedical Human Kinetics
·
16
PDF
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
2022
·
Paweł Rogala
, Anna M. Czarnecka
, et al.
·
Cancers
·
10
PDF
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
2022
·
Paweł Rogala
, Anna M. Czarnecka
, et al.
·
Journal of Clinical Medicine
·
10
PDF
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
2023
·
Karolina Piejko
, Bożena Cybulska-Stopa
, et al.
·
Targeted Oncology
·
8
PDF
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma
2021
·
Bożena Cybulska-Stopa
, Marcin Ziętek
, et al.
·
Journal of Dermatological Treatment
·
8
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
2020
·
Bożena Cybulska-Stopa
, Marcin Ziętek
, et al.
·
Melanoma Research
·
8
Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.
2021
·
Bozena Cybulska-Stopa
, Marcin Zietek
, et al.
·
Journal of Clinical Oncology
·
5
Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors
2025
·
Łukasz Galus
, Daria Tusień Małecka
, et al.
·
Współczesna Onkologia
·
3
PDF
Long-term efficacy of BRAFi/MEKi rechallenge in metastatic melanoma: Report of 9 years of clinical practice.
2023
·
Anna Malgorzata Czarnecka
, Bozena Cybulska-Stopa
, et al.
·
Journal of Clinical Oncology
·
3
PDF
1115P Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
2023
·
K. Piejko
, B. Cybulska-Stopa
, et al.
·
Annals of Oncology
·
2
PDF
Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data.
2022
·
Bozena Cybulska-Stopa
, Anna Malgorzata Czarnecka
, et al.
·
Journal of Clinical Oncology
·
2
Porównanie pośrednie wyników leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą niwolumabu lub pembrolizumabu – analiza wieloośrodkowa
2020
·
Bożena Cybulska-Stopa
, Marcin Ziętek
, et al.
·
Oncology in Clinical Practice
·
1
PDF
Immunotherapy or targeted therapy as first-line treatment of patients with advanced/metastatic melanoma with the BRAF mutation — a single-center analysis
2020
·
Bożena Cybulska-Stopa
, Karolina Piejko
, et al.
·
Oncology in Clinical Practice
·
1
PDF
Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?
2022
·
Bozena Cybulska-Stopa
, Anna Malgorzata Czarnecka
, et al.
·
Journal of Clinical Oncology
1087P The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
2021
·
B. Cybulska-Stopa
, A.M. Czarnecka
, et al.
·
Annals of Oncology
1117P Immunotherapy in octogenarian and nonagenarian metastatic melanoma patients
2020
·
B. Cybulska-Stopa
, M. Ziętek
, et al.
·
Annals of Oncology
Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.
2020
·
Bozena Cybulska-Stopa
, Iwona Lugowska
, et al.
·
Journal of Clinical Oncology
Immunoterapia czy terapia celowana w pierwszej linii leczenia chorych na zaawansowane/rozsiane czerniaki z obecnością mutacji BRAF — analiza jednoośrodkowa
2020
·
Bożena Cybulska-Stopa
, Karolina Piejko
, et al.
·
Onkologia w Praktyce Klinicznej - Edukacja
Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab
2019
·
B. Cybulska-Stopa
, K. Regulski
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
25
Citation count:
162
H-index:
8
I10-index:
8
Year
Topic
Type